Entera Bio prices $275 million private placement led by BVF Partners

Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a press release issued July 27, 2026.

The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management, among others.

Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to purchase up to 11,842,695 additional ordinary shares at the same base price, less a nominal exercise price of NIS 0.0000769 per share. The placement was priced at the market under Nasdaq rules and is expected to close on or about July 28, 2026.

Upon closing, Entera has agreed to grant BVF the right to designate two directors to its board, subject to applicable legal and Nasdaq requirements.

The company said it expects the net proceeds, combined with existing cash, to fund operations into 2030 and fully support Phase 3 registrational studies for EB613, its oral PTH(1-34) candidate being developed as a once-daily tablet for osteoporosis. Proceeds will also be used to advance EB612, an oral PTH(1-34) replacement therapy for hypoparathyroidism being developed in collaboration with OPKO Health, into Phase 1 development, as well as for general corporate purposes.

Leerink Partners is acting as lead placement agent. Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital, and Canaccord Genuity are serving as co-placement agents. The securities have not been registered under the Securities Act of 1933 and may not be resold in the United States absent an effective registration statement or applicable exemption.

You May Also Be Interested In

• 60 Degrees Pharmaceuticals raises $1M in private placement
• Fenbo Holdings gets Nasdaq minimum bid price deficiency notice
• Entera Bio prices $275M private placement led by BVF Partners